# Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy

> **NCT04115839** · PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 106 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Filgotinib
- **DRUG:** Placebo to match filgotinib

## Key facts

- **NCT ID:** NCT04115839
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-13
- **Primary completion:** 2021-01-04
- **Final completion:** 2021-03-18
- **Target enrollment:** 106 (ACTUAL)
- **Why stopped:** Development program terminated
- **Last updated:** 2022-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04115839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04115839, "Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT04115839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*